加载中
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
常规交易时段
US$2.025
−US$0.105 · -4.93%
盘中时间采用ET。市场数据可能有所延迟。
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
日内区间
当前US$2.025
52周区间
当前US$2.025
盘中时间采用ET。市场数据可能有所延迟。
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
日内区间
当前US$2.025
52周区间
当前US$2.025
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.49亿 USD | 7489万 USD | 7134.8万 USD | 6520.6万 USD | 5531.2万 USD |
| 销货成本 | 7684.9万 USD | 2072.9万 USD | 1964.3万 USD | 1548.3万 USD | 1165.3万 USD |
| 毛利 | 7230.8万 USD | 5416.1万 USD | 5170.5万 USD | 4972.3万 USD | 4365.9万 USD |
| 研究与开发 | 658.4万 USD | 1277.1万 USD | 951.5万 USD | 933.6万 USD | 792.3万 USD |
| 销售、一般及管理费用 | 9716万 USD | 7595.3万 USD | 7274.4万 USD | 7549.8万 USD | 6330万 USD |
| 营业费用 | 1.04亿 USD | 8872.4万 USD | 8225.9万 USD | 8483.4万 USD | 7122.3万 USD |
| 利息收入 | — | — | 2.4万 USD | — | — |
| 利息支出 | 841.5万 USD | 728.6万 USD | 542.4万 USD | 360万 USD | 330万 USD |
| 折旧和摊销 | 346.5万 USD | 207.3万 USD | 200.6万 USD | 164.8万 USD | 106万 USD |
| 营业利润 | −3143.6万 USD | −3456.3万 USD | −3055.4万 USD | −3511.1万 USD | −2756.4万 USD |
| 净利润 | −3899.8万 USD | −4370.8万 USD | −3018.9万 USD | −3715.9万 USD | −3119.3万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.00
上涨空间 146.91%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI300.04万0.00%2.3万亿 USD0.03%US$381.33-0.06%
AdvisorShares Psychedelics ETFPSIL182.89万4.00%4574.2万 USD1.84%US$20.555-3.27%
Vanguard Extended Market ETFVXF136.03万0.00%954亿 USD0.05%US$232.58-0.40%
iShares Micro-Cap ETFIWC19.12万0.01%13.17亿 USD0.60%US$180.11-0.86%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM19万0.17%1.16亿 USD0.73%US$15.68-1.06%
Invesco NASDAQ Future Gen 200 ETFQQQS8.99万0.40%2275.83万 USD0.20%US$40.715-1.69%Vanguard Morningstar Total Stock Market ETFVTIAdvisorShares Psychedelics ETFPSILVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
